TribLIVE

| Business


 
Larger text Larger text Smaller text Smaller text | Order Photo Reprints

Merck, Pfizer sue to block proposed version of AzaSite

Email Newsletters

Click here to sign up for one of our email newsletters.

On the Grid

From the shale fields to the cooling towers, Trib Total Media covers the energy industry in Western Pennsylvania and beyond. For the latest news and views on gas, coal, electricity and more, check out On the Grid today.

MRK $47.80 -$0.15

PFE $29.16 +$0.07

MYL $31.54 -$0.14

at close on MONDAY

Daily Photo Galleries

By Bloomberg News
Tuesday, June 18, 2013, 12:01 a.m.
 

Merck & Co. and Pfizer Inc. sued generic drugmaker Mylan Pharmaceuticals Inc. to block it from selling a copy of AzaSite, an antibiotic eye solution for fighting bacterial conjunctivitis.

Mylan told Pfizer, Merck and InSite Vision Inc. on May 1 that it sought Food and Drug Administration approval to sell a generic version of AzaSite, according to a lawsuit filed on Friday in federal court in Trenton, N.J. The complaint asks a judge to prevent Mylan from entering the market before the patents expire. One ends in 2018, and the other three expire in 2019, according to the FDA website.

Subscribe today! Click here for our subscription offers.

 

 


Show commenting policy

Most-Read Business Headlines

  1. Financial planning for disabled people a little-tapped field
  2. AT&T evolves beyond phones
  3. This robot is cute, artificially intelligent and employed
  4. How to cover work history gaps
  5. Keep pesky neighbors from stealing your Internet
  6. FAA: Cockpit email system reduces delays
  7. Taxes matter in  fund investing, even when there’s no bill
  8. Shareholder vote causes ATI to review executive pay packages
  9. Drenching rains green pastures, bode well for cattle herd expansion in Great Plains
  10. Cheap oil can hurt economy
  11. Parent of Lane Bryant, Justice to buy owner of Ann Taylor for $2B